← Back to Clinical Trials
RecruitingNCT07106970

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionPersistent Atrial Fibrillation
SponsorBoston Scientific Corporation
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment640
SexALL
Min Age18 Years
Max Age80 Years
Start Date2025-08-28
Completion2027-09-30
Interventions
Linear ablationPVI alone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)

Eligibility Criteria

Inclusion Criteria: Study subjects are required to meet all the following inclusion criteria: 1. Subjects with an age range of 18 years or above and 80 years or below. 2. Subjects have symptomatic, drug-resistant, persistent AF, defined as: 1. Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath. 2. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one AAD. 3. Persistent: continuous AF for \> 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous ECG recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart. 3. Subjects undergoing a first-time ablation procedure for AF. 4. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study. Exclusion Criteria: 1. AF that is secondary to elect

Related Trials